Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis

Rheumatology

Volumn 44, Issue 7, 2005, Pages 873-878

  Hayakawa, I ^a   Hasegawa, Minoruha ^a   Matsushita, T ^a   Yanaba, K ^a   Kodera, M ^a   Komura, K ^a   Takehara, K ^a   Sato, S ^a,b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

CTACK; Cutaneous T cell attracting chemokine; Systemic sclerosis

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE; MESSENGER RNA; BETA CHEMOKINE; CCL27 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN CALCIFICATION; SKIN CELL; SKIN INFLAMMATION; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; BIOSYNTHESIS; BLOOD; GENE EXPRESSION; GENETICS; HOSPITALIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SKIN;

ADULT; C-REACTIVE PROTEIN; CHEMOKINES, CC; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 22844452819     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh625     Document Type: Article

References (35)

1. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996;32:695-708.
2. Furst DE. Rational therapy in the treatment of systemic sclerosis. Curr Opin Rheumatol 2000;12:540-4.
3. Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997;24(Suppl. 48):53-7.
4. Steen VD, Medsger TA Jr. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 1990;16:1-10.
5. White B. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1995;7:541-5.
6. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000;43:2550-62.
7. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
8. Kahari VM. Activation of dermal connective tissue in scleroderma. Ann Med 1993;25:511-8.
9. Domagala-Kulawik J, Hoser G, Kawalec M, Doboszynska A, Kawiak J, Droszcz W. Lymphocyte phenotyping in systemic sclerosis: A flow cytometry analysis of lymphocytes in bronchoalveolar lavage fluid. Anal Quant Cytol Histol 1997;19:264-70.
10. Wells AU, Lorimer S, Majumdar S et al. Fibrosing alveolitis in systemic sclerosis: Increase in memory T-cells in lung interstitium. Eur Respir J 1995;8:266-71.
11. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
12. Gruschwitz M, von den Driesch P, Kellner I, Hornstein OP, Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992;27:169-77.
13. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000;12:121-7.
14. Homey B, Zlotnik A. Chemokines in allergy. Curr Opin Immunol 1999;11:626-34.
15. Homey B, Alenius H, Muller A et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002;8:157-65.
16. Committee SfSCotARADaTC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
17. LeRoy EC, Krieg T, Black C et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
18. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
19. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
21. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-8.
22. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
23. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
24. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: Association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
25. Ihn H, Sato S, Fujimoto M et al. Measurement of anticardiolipin antibodies by ELISA using β2-glycoprotein I (β2-GPI) in systemic sclerosis. Clin Exp Immunol 1996;105:475-9.
26. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001;3:55-61.
27. Kakinuma T, Saeki H, Tsunemi Y et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 2003;111:592-7.
28. Hijnen D, De Bruin-Weller M, Oosting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004;113:334-40.
29. Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 2004;22:S87-9.
30. Morales J, Horney B, Vicari AP et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999;96:14470-5.
31. Vestergaard C, Deleuran M, Gesser B, Larsen CG. Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice. Exp Dermatol 2004;13:265-71.
32. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 2004;35:43-51.
33. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated Serum tumor necrosis factor-α levels in patients with systemic sclerosis: association wiih pulmonary fibrosis. J Rheumatol 1997; 24:663-5.
34. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997;40:746-51.
35. Gruschwitz MS, Albrecht M, Vieth G, Haustein UF. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997; 24:1936-43.